Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $412.91 million. The enterprise value is $663.25 million.
Important Dates
The next confirmed earnings date is Monday, November 11, 2024, after market close.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.85 million shares outstanding. The number of shares has increased by 0.47% in one year.
| Shares Outstanding | 62.85M |
| Shares Change (YoY) | +0.47% |
| Shares Change (QoQ) | -4.44% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 12.09% |
| Float | 27.62M |
Valuation Ratios
The trailing PE ratio is 128.57 and the forward PE ratio is 16.32. BIOX's PEG ratio is 1.36.
| PE Ratio | 128.57 |
| Forward PE | 16.32 |
| PS Ratio | 0.89 |
| Forward PS | 0.75 |
| PB Ratio | 1.31 |
| P/FCF Ratio | 12.93 |
| PEG Ratio | 1.36 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 11.44, with an EV/FCF ratio of 20.77.
| EV / Earnings | 204.49 |
| EV / Sales | 1.43 |
| EV / EBITDA | 11.44 |
| EV / EBIT | 16.27 |
| EV / FCF | 20.77 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.24 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 4.41 |
| Debt / FCF | 8.49 |
| Interest Coverage | 1.69 |
Financial Efficiency
Return on equity (ROE) is 1.84% and return on invested capital (ROIC) is 4.22%.
| Return on Equity (ROE) | 1.84% |
| Return on Assets (ROA) | 3.05% |
| Return on Capital (ROIC) | 4.22% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | $8,338 |
| Employee Count | 389 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.12 |
Taxes
In the past 12 months, BIOX has paid $3.78 million in taxes.
| Income Tax | 3.78M |
| Effective Tax Rate | 37.65% |
Stock Price Statistics
The stock price has decreased by -38.57% in the last 52 weeks. The beta is 0.47, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -38.57% |
| 50-Day Moving Average | 8.22 |
| 200-Day Moving Average | 10.96 |
| Relative Strength Index (RSI) | 22.76 |
| Average Volume (20 Days) | 171,895 |
Short Selling Information
| Short Interest | 623,597 |
| Short Previous Month | 611,075 |
| Short % of Shares Out | 0.99% |
| Short % of Float | 2.26% |
| Short Ratio (days to cover) | 4.03 |
Income Statement
In the last 12 months, BIOX had revenue of $464.83 million and earned $3.24 million in profits. Earnings per share was $0.05.
| Revenue | 464.83M |
| Gross Profit | 181.59M |
| Operating Income | 40.77M |
| Pretax Income | 9.30M |
| Net Income | 3.24M |
| EBITDA | 57.98M |
| EBIT | 40.77M |
| Earnings Per Share (EPS) | $0.05 |
Full Income StatementBalance Sheet
The company has $56.17 million in cash and $270.95 million in debt, giving a net cash position of -$214.78 million or -$3.42 per share.
| Cash & Cash Equivalents | 56.17M |
| Total Debt | 270.95M |
| Net Cash | -214.78M |
| Net Cash Per Share | -$3.42 |
| Equity (Book Value) | 349.56M |
| Book Value Per Share | 5.00 |
| Working Capital | 79.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $41.72 million and capital expenditures -$9.79 million, giving a free cash flow of $31.93 million.
| Operating Cash Flow | 41.72M |
| Capital Expenditures | -9.79M |
| Free Cash Flow | 31.93M |
| FCF Per Share | $0.51 |
Full Cash Flow StatementMargins
Gross margin is 39.07%, with operating and profit margins of 8.77% and 0.70%.
| Gross Margin | 39.07% |
| Operating Margin | 8.77% |
| Pretax Margin | 2.16% |
| Profit Margin | 0.70% |
| EBITDA Margin | 12.47% |
| EBIT Margin | 8.77% |
| FCF Margin | -2.67% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.47% |
| Shareholder Yield | -0.47% |
| Earnings Yield | 0.79% |
| FCF Yield | 7.73% |
Analyst Forecast
The average price target for BIOX is $14.00, which is 113.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 113.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 21.17% |
| EPS Growth Forecast (5Y) | 120.98% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOX has an Altman Z-Score of 1.71 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.71 |
| Piotroski F-Score | 5 |